Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
about
Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transportersRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceNew trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapiesThe FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsPharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Transmembrane helices 1 and 6 of the human breast cancer resistance protein (BCRP/ABCG2): identification of polar residues important for drug transport.Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor.Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapyThe skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.Identification of proline residues in or near the transmembrane helices of the human breast cancer resistance protein (BCRP/ABCG2) that are important for transport activity and substrate specificity.Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1.Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.Marginal increase of sunitinib exposure by grapefruit juice.Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.The challenge of exploiting ABCG2 in the clinic.Inhibition of multidrug resistance-linked P-glycoprotein (ABCB1) function by 5'-fluorosulfonylbenzoyl 5'-adenosine: evidence for an ATP analogue that interacts with both drug-substrate-and nucleotide-binding sitesABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data.Activation of alternate prosurvival pathways accounts for acquired sunitinib resistance in U87MG glioma xenografts.Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft modelsGenistein and Glyceollin Effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells.Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic fluxThe novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2Biochemical mechanism of modulation of human P-glycoprotein by stemofolineIn vitro and in vivo modulation of ABCG2 by functionalized aurones and structurally related analogs.Reversing multidrug resistance by tyrosine kinase inhibitorsThe ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivoThe Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanismsPharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.Targeting CD133 antigen in cancer.Design, synthesis, and biological evaluation of (S)-valine thiazole-derived cyclic and noncyclic peptidomimetic oligomers as modulators of human P-glycoprotein (ABCB1).ABC transporters in human lymphocytes: expression, activity and role, modulating factors and consequences for antiretroviral therapies.New insights into therapeutic activity and anticancer properties of curcumin.
P2860
Q24617999-7FCBECA2-4F8D-4150-B4AA-7DECDFBC6E3AQ26865927-211F557B-78C3-48EB-951C-8712A06FAE60Q28067499-64473342-C835-4FCB-8F3E-4B4D9BA2B63FQ28535342-C59F461A-7474-4CAA-8E89-D439994099DCQ33410206-3A78F177-CE03-4EFD-B972-904C931C21C1Q33672739-19139030-6D40-4F2A-B1EB-3A005E6016FFQ33726782-F749760F-73B4-45B1-A44E-745D9EEE4777Q33828409-5B7807E0-4153-46A3-8CCD-39322D99E952Q33891947-77C40DE5-5202-42FD-879D-AF4AD9FD8B74Q33997565-832B6CA6-C8D8-471D-BE52-7CBAA21B3456Q34046157-E99096D4-4289-482F-97F7-38C86E97C4EBQ34176588-47D4D289-1DE4-4EEA-9780-6DCF0722BEF6Q34458602-CD4B098D-505D-43A3-898E-463D8339B1D2Q34594877-6C21DEBA-4311-4FA0-BC99-0FA91D2F7748Q34795914-0D2E329F-D226-4FAB-AEFA-D0AB3CBD7AB0Q34968909-0D78C889-ECE0-407F-849D-05BEF81ABCAAQ35025897-80A63E2A-6BB0-499D-A053-CA1965D16A14Q35171274-B825C5CB-737B-41D3-BBFE-75023B27A7B2Q35708124-77873E2C-80DB-441A-AC21-1EA9F8F465B2Q35946822-6209430C-990C-4675-AA87-CB5F077B43D0Q36185372-922765F9-EB80-4406-B0FB-054C209D49E7Q36308299-82338F71-AC8D-4D7B-AB5B-C9B3A40A3C00Q36309864-56B0E4AD-AF70-459E-887D-DABEE144B1DBQ36335477-9D7FFE2E-7DEE-4CD5-B81D-BE5B6B31A7D4Q36442931-2AEB1FF7-9C10-45E3-B4A3-73F546483DDAQ36512849-ABC15E70-954C-41FF-9D75-9A68898AC212Q36618871-74008B85-9487-4317-826C-C3C46A5204EAQ36777194-F0926C05-B21B-47EA-8D33-49F26AF51F47Q36933169-1C020DF1-02BC-42B2-B0FC-6DDEDD0A07D3Q37051244-3104C548-8A46-4DB3-B61C-CC310CFA21C2Q37070476-5F5BA39B-A6BE-4822-B828-913C8280027DQ37183670-DBAFF4C3-84EA-41F1-B93E-653214E5C434Q37253610-5848BBBB-0511-4A7F-AA33-203E0D643D9CQ37289700-4F82F03E-8536-4FEC-AA1D-D571692E12B5Q37331814-D2555E26-9C06-4E80-BD92-7BFB4BB64798Q37333659-52952189-A91B-4189-992D-3F2130AFCA08Q37521082-49A315B5-7226-4F4E-AD78-1123F6E9EF89Q37527758-4693601A-CC96-4078-8981-8FD640870354Q37724178-EB3BD8B4-AB68-457F-B668-C0068346EDA9Q37745657-B67E1392-3FB6-478E-B77E-E18D0DEA8994
P2860
Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sunitinib (Sutent, SU11248), a ...... lycoprotein (ABCB1) and ABCG2.
@en
Sunitinib (Sutent, SU11248), a ...... lycoprotein (ABCB1) and ABCG2.
@nl
type
label
Sunitinib (Sutent, SU11248), a ...... lycoprotein (ABCB1) and ABCG2.
@en
Sunitinib (Sutent, SU11248), a ...... lycoprotein (ABCB1) and ABCG2.
@nl
prefLabel
Sunitinib (Sutent, SU11248), a ...... lycoprotein (ABCB1) and ABCG2.
@en
Sunitinib (Sutent, SU11248), a ...... lycoprotein (ABCB1) and ABCG2.
@nl
P2093
P2860
P356
P1476
Sunitinib (Sutent, SU11248), a ...... lycoprotein (ABCB1) and ABCG2.
@en
P2093
Robert W Robey
Suneet Shukla
Suresh V Ambudkar
Susan E Bates
P2860
P304
P356
10.1124/DMD.108.024612
P577
2008-10-29T00:00:00Z